title: PON1 Q192R and clopidogrel: a case of the winner's curse or inadequate replication?
abstract: The antiplatelet drug clopidogrel is one of the most commonly prescribed drugs in the world, but there is wide interpatient variability in its antiplatelet effects. The majority of this variation is due to genetic effects, but there is controversy over which genetic variants are important and their relative contribution. This controversy may stem from the genetic association research paradigm, which casts the "winner's curse."
authors.affiliation: UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, North Carolina, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Talameh
authors.forename: H L
authors.initials: HL
authors.lastname: McLeod
mesh_terms: D043303:Aryldialkylphosphatase / Q000235:genetics*; D002318:Cardiovascular Diseases / Q000235:genetics* / Q000401:mortality*; D005260:Female; D056726:Genetic Association Studies / Q000379:methods*; D014644:Genetic Variation / Q000235:genetics*; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*; D013988:Ticlopidine / Q000031:analogs & derivatives*
chemical_list: D043303:Aryldialkylphosphatase; D013988:Ticlopidine